SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 73 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $338,617 | -39.3% | 16,033 | -26.8% | 0.00% | -100.0% |
Q4 2022 | $557,457 | -17.4% | 21,904 | -21.9% | 0.00% | 0.0% |
Q3 2022 | $675,000 | +63.8% | 28,064 | +31.1% | 0.00% | – |
Q2 2022 | $412,000 | +24.1% | 21,408 | +8.0% | 0.00% | – |
Q1 2022 | $332,000 | +253.2% | 19,826 | +131.3% | 0.00% | – |
Q1 2020 | $94,000 | +184.8% | 8,572 | +93.1% | 0.00% | – |
Q3 2019 | $33,000 | – | 4,440 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |